Response to Sexton: Inhibiting the renin-angiotensin-aldosterone system in patients with heart failure and renal dysfunction: common sense or nonsense?
From the Cardiology Division, Emory University, Atlanta, GA (J.B.); and Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.M.G.). javed.butler@emory.edu mgivertz@partners.org.
Javed
J
Butler
From the Cardiology Division, Emory University, Atlanta, GA (J.B.); and Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.M.G.).
Michael M
MM
Givertz
D059347:Cardio-Renal Syndrome / Q000503:physiopathology*; D006333:Heart Failure / Q000503:physiopathology*; D006801:Humans; D051436:Renal Insufficiency, Chronic / Q000503:physiopathology*; D012084:Renin-Angiotensin System / Q000502:physiology*
angiotensin receptor antagonists; angiotensin-converting enzyme inhibitors; heart failure; hypotension; mineralocorticoid receptor antagonists; renal insufficiency; renin–angiotensin system